JACC. Heart failure最新文献

{"title":"Validation of Guideline Recommendation on Sudden Cardiac Death Prevention in Hypertrophic Cardiomyopathy","authors":"Masashi Amano MD, PhD ,&nbsp;Hiroaki Kitaoka MD, PhD ,&nbsp;Yusuke Yoshikawa MD, PhD, MPH ,&nbsp;Yasushi Sakata MD, PhD ,&nbsp;Kaoru Dohi MD, PhD ,&nbsp;Yukichi Tokita MD, PhD ,&nbsp;Takao Kato MD, PhD ,&nbsp;Shouji Matsushima MD, PhD ,&nbsp;Takeshi Kitai MD, PhD ,&nbsp;Atsushi Okada MD, PhD ,&nbsp;Yutaka Furukawa MD, PhD ,&nbsp;Toshihiro Tamura MD, PhD ,&nbsp;Akihiro Hayashida MD ,&nbsp;Haruhiko Abe MD ,&nbsp;Kenji Ando MD ,&nbsp;Satoshi Yuda MD, PhD ,&nbsp;Moriaki Inoko MD, PhD ,&nbsp;Kazushige Kadota MD, PhD ,&nbsp;Yukio Abe MD, PhD ,&nbsp;Katsuomi Iwakura MD, PhD ,&nbsp;Soichiro Kobayashi","doi":"10.1016/j.jchf.2024.12.006","DOIUrl":"10.1016/j.jchf.2024.12.006","url":null,"abstract":"<div><h3>Background</h3><div>To prevent sudden cardiac death (SCD) in patients with hypertrophic cardiomyopathy (HCM), the HCM Risk-SCD calculator and guideline recommendations are used to aid decision making for implantable cardioverter-defibrillator placement.</div></div><div><h3>Objectives</h3><div>The aim of this study was to assess the clinical profiles and occurrence of SCD by phenotypes of HCM and validate the performance of the current guidelines from a large-scale Japanese multicenter registry.</div></div><div><h3>Methods</h3><div>This was a retrospective, multicenter, observational, longitudinal cohort study that enrolled 3,611 consecutive patients with HCM. The primary endpoint was a composite of SCD or an equivalent event.</div></div><div><h3>Results</h3><div>The 5-year cumulative incidence of SCD events was markedly high in patients with end-stage HCM, defined by ejection fraction &lt;50% (18.5%), followed by midventricular obstruction and nonobstructive HCM (6.9% and 4.7%). The 5-year cumulative incidence rates of SCD events for each recommendation class by the 2 guidelines were as follows: with the 2024 ACC (American College of Cardiology)/AHA (American Heart Association) guidelines, 23.8%, 7.2%, 5.7%, and 2.3% for Classes 1, 2a, 2b, and 3, respectively, and with the 2023 ESC (European Society of Cardiology) guidelines, 23.8%, 2.9%, 9.3%, and 2.6%, respectively. The 5-year risk was not well stratified between Classes 2a and 2b with the 2024 ACC/AHA guidelines (<em>P =</em> 0.101), and the event rate was even reversed with the 2023 ESC guidelines (<em>P =</em> 0.545).</div></div><div><h3>Conclusions</h3><div>Among HCM phenotypes, the prognosis of patients with end-stage HCM was markedly worse. The 2024 ACC/AHA and 2023 ESC guidelines well stratified SCD risk in patients with HCM; the 2024 ACC/AHA guidelines seemed to better stratify SCD risk between Classes 2a and 2b compared with the 2023 ESC guidelines.</div></div>","PeriodicalId":14687,"journal":{"name":"JACC. Heart failure","volume":"13 6","pages":"Pages 1014-1026"},"PeriodicalIF":10.3,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143633903","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-Term Response of Obstructive Hypertrophic Cardiomyopathy Patients to Mavacamten Based on Sex","authors":"Milind Y. Desai MD, MBA ,&nbsp;Sara Saberi MD, MS ,&nbsp;Jeffrey B. Geske MD ,&nbsp;Andrew Wang MD ,&nbsp;Paul Cremer MD, MS ,&nbsp;David R. Fermin MD ,&nbsp;Mark A. Zenker MD ,&nbsp;Neal K. Lakdawala MD ,&nbsp;Albree Tower-Rader MD ,&nbsp;Srihari S. Naidu MD ,&nbsp;Kathy Lampl MD ,&nbsp;Anjali Owens MD ,&nbsp;the VALOR-HCM Investigators","doi":"10.1016/j.jchf.2025.02.005","DOIUrl":"10.1016/j.jchf.2025.02.005","url":null,"abstract":"","PeriodicalId":14687,"journal":{"name":"JACC. Heart failure","volume":"13 6","pages":"Pages 1037-1040"},"PeriodicalIF":10.3,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143657183","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Initial Experience With Aeson Total Artificial Heart in Cardiogenic Shock Patients on Extracorporeal Life Support","authors":"Anne-Céline Martin MD, PhD ,&nbsp;Mouhamed D. Moussa MD, PhD ,&nbsp;Bernd Panholzer MD ,&nbsp;Alessandro Verde MD, PhD ,&nbsp;Julien Guihaire MD, PhD ,&nbsp;Hug Aubin MD, MHBA ,&nbsp;Alexey Dashkevich MD ,&nbsp;Johannes Kroll MD ,&nbsp;Alexandre Mebazaa MD, PhD ,&nbsp;Marco Metra MD, PhD ,&nbsp;Federico Pappalardo MD","doi":"10.1016/j.jchf.2025.01.023","DOIUrl":"10.1016/j.jchf.2025.01.023","url":null,"abstract":"","PeriodicalId":14687,"journal":{"name":"JACC. Heart failure","volume":"13 6","pages":"Pages 1030-1033"},"PeriodicalIF":10.3,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143772330","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Carvedilol as Single Therapy for Heart Failure With Improved Ejection Fraction","authors":"Deborah de Sá Pereira Belfort PhD ,&nbsp;Edimar Alcides Bocchi PhD ,&nbsp;Caio Rebouças Fonseca Cafezeiro PhD ,&nbsp;Mauro R.B. Wanderley Jr. PhD ,&nbsp;Vera Maria Cury Salemi PhD ,&nbsp;Camila Rocon PhD ,&nbsp;Robinson Tadeu Munhoz PhD ,&nbsp;Paulo Roberto Chizzola PhD ,&nbsp;Bruno Biselli MD ,&nbsp;Diógenes Amauri Gonçalves Furlan MD ,&nbsp;Silvia Moreira Ayub-Ferreira PhD","doi":"10.1016/j.jchf.2025.02.022","DOIUrl":"10.1016/j.jchf.2025.02.022","url":null,"abstract":"","PeriodicalId":14687,"journal":{"name":"JACC. Heart failure","volume":"13 6","pages":"Pages 1041-1044"},"PeriodicalIF":10.3,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144078184","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prospective Validation and Implementation Pilot Study of an Emergency Department Heart Failure Risk Stratification Tool","authors":"Dana R. Sax MD, MPH ,&nbsp;Jie Huang PhD ,&nbsp;Dustin G. Mark MD ,&nbsp;Jamal S. Rana MD, PhD ,&nbsp;Mathew S. Solomon MD, PhD ,&nbsp;Robert P. Norris MD ,&nbsp;Mary E. Reed DrPH","doi":"10.1016/j.jchf.2025.01.018","DOIUrl":"10.1016/j.jchf.2025.01.018","url":null,"abstract":"<div><h3>Background</h3><div>The STRIDE-HF (Systematic Tool for Risk Identification and Decision-making in Emergency Heart Failure) emergency department (ED) risk tool was previously found to accurately predict the risk of a 30-day serious adverse event (SAE), including 30-day mortality, cardiopulmonary resuscitation, intra-aortic balloon pump insertion, intubation, new dialysis, myocardial infarction, or coronary revascularization.</div></div><div><h3>Objectives</h3><div>The aim of this study was to prospectively validate STRIDE-HF across 21 community EDs among patients in the ED with acute heart failure (AHF) from January 1, 2023, to December 31, 2023, and to assess the safety of the real-time use of risk estimates in a 2-ED pilot study.</div></div><div><h3>Methods</h3><div>Model area under the receiver operator curve (AUROC) and area under the precision recall curve (AUPRC), sensitivity, specificity, and positive and negative predictive values and likelihood ratios at key clinical thresholds are reported. In the clinical pilot, the rates of 30-day SAEs among patients who were at lower risk by STRIDE-HF and were discharged after ED or observation care were reported.</div></div><div><h3>Results</h3><div>There were 13,274 patients in the ED in the prospective validation; the median age was 76 years, 50.8% were female, and 44.5% were non-White; and 11.4%, 24.8%, 31.9%, and 31.9% of patients were at very low, low, moderate, and high risk, respectively. The 30-day SAE rates among very–low-risk and low-risk patients were 3.4% and 6.7%, respectively, and the 30-day mortality rates were &lt;1% and &lt;2%, respectively. STRIDE-HF was highly sensitive among low-risk patients (97.6%; 95% CI: 96.8%-98.2%); AUROC was 0.75 (95% CI: 0.74-0.76), and AUPRC was 0.43 (95% CI: 0.39-0.44). There were 845 patients in the pilot study; among patients classified by STRIDE-HF criteria as being at very low risk who were discharged, none experienced a 30-day SAE.</div></div><div><h3>Conclusions</h3><div>STRIDE-HF maintained high predictive accuracy for 30-day SAE in prospective validation in this large, diverse, multicenter cohort; the use of risk estimates in real time safely identified low-risk patients appropriate for discharge.</div></div>","PeriodicalId":14687,"journal":{"name":"JACC. Heart failure","volume":"13 6","pages":"Pages 958-969"},"PeriodicalIF":10.3,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143990363","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Risk Stratification in Acute Heart Failure","authors":"Chang (Nancy) Wang MD, MSc ,&nbsp;Douglas S. Lee MD, PhD","doi":"10.1016/j.jchf.2025.02.013","DOIUrl":"10.1016/j.jchf.2025.02.013","url":null,"abstract":"","PeriodicalId":14687,"journal":{"name":"JACC. Heart failure","volume":"13 6","pages":"Pages 970-972"},"PeriodicalIF":10.3,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143991042","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Searching for Volume in All the Wrong Places","authors":"Sean P. Pinney MD","doi":"10.1016/j.jchf.2025.04.005","DOIUrl":"10.1016/j.jchf.2025.04.005","url":null,"abstract":"","PeriodicalId":14687,"journal":{"name":"JACC. Heart failure","volume":"13 6","pages":"Pages 1011-1013"},"PeriodicalIF":10.3,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144194910","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Results of the Precision Event Monitoring for Patients With Heart Failure Using HeartLogic Study (PREEMPT-HF)","authors":"Andrew J. Sauer MD ,&nbsp;Craig M. Stolen PhD ,&nbsp;Jonathan B. Shute PhD ,&nbsp;Brian Kwan MS ,&nbsp;Ramesh Wariar PhD ,&nbsp;Stephen B. Ruble PhD ,&nbsp;Roy S. Gardner MD ,&nbsp;John P. Boehmer MD","doi":"10.1016/j.jchf.2025.01.028","DOIUrl":"10.1016/j.jchf.2025.01.028","url":null,"abstract":"<div><h3>Background</h3><div>Improved patient monitoring and management after heart failure (HF) hospitalizations are needed to reduce readmissions significantly.</div></div><div><h3>Objectives</h3><div>The aim of this study was to investigate the association between monitoring data and readmissions.</div></div><div><h3>Methods</h3><div>PREEMPT-HF (PRecision Event Monitoring for PatienTs with Heart Failure using HeartLogic) was a global, observational, single-arm study enrolling adult HF patients remotely monitored with HeartLogic-capable implantable cardioverter-defibrillator and cardiac resynchronization therapy devices. Patients and clinicians were blinded to the index and alerts. Participants were followed for 12 months for site reporting of events.</div></div><div><h3>Results</h3><div>A total of 2,155 patients were enrolled at 103 sites and were monitored remotely (39% implantable cardioverter-defibrillators and 61% cardiac resynchronization therapy-defibrillators). There were 243 hospitalizations for HF, of which 156 (64%) were index hospitalizations. There were 25 (28%) unplanned all-cause readmissions in the 30 days after discharge and 45 (46%) all-cause readmissions within 90 days. Alert sensitivity for outpatient visits and hospitalizations for HF was 78.3%, and the false-positive rate was 1.18/year. The HeartLogic index was higher before index hospitalizations for HF when followed by HF or readmission for all causes. Index hospitalizations for HF were also more likely to be followed by readmission for HF in 90 days if the patient was in an alert state (vs out-of-alert state) 1 or 2 weeks before or 2 weeks after the index admission.</div></div><div><h3>Conclusions</h3><div>HeartLogic index trends were significantly different for patients who were readmitted for HF. These trends suggest that individuals at risk for readmission have had a more sustained worsening and/or insufficient intervention during the initial hospitalization for HF. (PRecision Event Monitoring for PatienTs with Heart Failure using HeartLogic [PREEMPT-HF]; <span><span>NCT03579641</span><svg><path></path></svg></span>)</div></div>","PeriodicalId":14687,"journal":{"name":"JACC. Heart failure","volume":"13 6","pages":"Pages 973-983"},"PeriodicalIF":10.3,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144004015","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tricuspid Regurgitation in Left Ventricular Assist Device","authors":"Boaz Elad MD ,&nbsp;Emily Tat MD ,&nbsp;Gabriel Sayer MD ,&nbsp;Koji Takeda MD ,&nbsp;Michael I. Brener MD ,&nbsp;Dor Lotan MD ,&nbsp;Daniel Burkhoff MD, PhD ,&nbsp;Susheel Kodali MD ,&nbsp;Rebecca Hahn MD ,&nbsp;Martin B. Leon MD ,&nbsp;Nir Uriel MD, MSc","doi":"10.1016/j.jchf.2025.03.031","DOIUrl":"10.1016/j.jchf.2025.03.031","url":null,"abstract":"<div><div>The presence of tricuspid regurgitation (TR) in patients with heart failure is associated with poor outcomes. Similarly, TR in patients with durable left ventricular assist device (LVAD) support is associated with increased morbidity and mortality. The role of tricuspid valve (TV) intervention to correct TR at the time of LVAD implantation remains uncertain because multiple studies thus far have shown conflicting results on clinical outcomes. This review discusses the mechanism of TR in LVAD recipients, the hemodynamic effects of TR after LVAD implantation, and the significance of corrected and uncorrected TR in the context of LVAD support. It also examines predictors of TR following LVAD implantation and highlights the discrepancies and gaps in the existing published reports. Finally, the review evaluates the potential role of novel transcatheter tricuspid therapies in these patients.</div></div>","PeriodicalId":14687,"journal":{"name":"JACC. Heart failure","volume":"13 6","pages":"Pages 901-911"},"PeriodicalIF":10.3,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144194449","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of Acute Phase Intensive Exercise Training in Patients With Acute Decompensated Heart Failure","authors":"Kentaro Kamiya PT, PhD ,&nbsp;Shinya Tanaka PT, PhD ,&nbsp;Hiroshi Saito PT, PhD ,&nbsp;Masashi Yamashita PT, PhD ,&nbsp;Ryusuke Yonezawa PT, PhD ,&nbsp;Nobuaki Hamazaki PT, PhD ,&nbsp;Ryota Matsuzawa PT, PhD ,&nbsp;Kohei Nozaki PT, PhD ,&nbsp;Yoshiko Endo PT ,&nbsp;Kazuki Wakaume PT, MSc ,&nbsp;Shota Uchida PT, PhD ,&nbsp;Emi Maekawa MD, PhD ,&nbsp;Yuya Matsue MD, PhD ,&nbsp;Makoto Suzuki MD, PhD ,&nbsp;Takayuki Inomata MD, PhD ,&nbsp;Junya Ako MD, PhD","doi":"10.1016/j.jchf.2024.11.006","DOIUrl":"10.1016/j.jchf.2024.11.006","url":null,"abstract":"<div><h3>Background</h3><div>Acute decompensated heart failure (ADHF) leads to hospitalizations and functional decline in older adults. Although cardiac rehabilitation (CR) is effective for stable heart failure, its impact on ADHF patients, particularly those without frailty, is unclear.</div></div><div><h3>Objectives</h3><div>The goal of this study was to evaluate the efficacy and safety of early in-hospital CR for patients hospitalized with ADHF who are not frail.</div></div><div><h3>Methods</h3><div>In this multicenter trial (ACTIVE-ADHF [Effects of Acute Phase Intensive Exercise Training in Patients with Acute Decompensated Heart Failure]), ADHF patients without physical frailty were randomized 2:1 to undergo either exercise-based CR or standard care. The intervention included early mobilization and structured exercise training. The primary outcome was the change in 6-minute walk distance (6MWD) from baseline to discharge. Secondary outcomes assessed physical and cognitive function, quality of life, and safety.</div></div><div><h3>Results</h3><div>A total of 91 patients were randomized to treatment, with 59 allocated to the intervention group and 32 to the control group. The primary outcome, 6MWD, improved significantly more in the intervention group, with a mean increase of 75.0 ± 7.8 m vs 44.1 ± 10.2 m in the control group, with an effect size of 30.9 ± 13.1 m (95% CI: 4.8-57.0; <em>P =</em> 0.021). The intervention group showed favorable results in secondary efficacy outcomes, including physical and cognitive function, physical activity, and quality of life. Safety outcomes were similar between groups, except for a greater reduction in B-type natriuretic peptide levels at 90 days’ postdischarge in the intervention group.</div></div><div><h3>Conclusions</h3><div>In patients with ADHF without physical frailty, in-hospital exercise-based CR led to significant improvements in 6MWD at 2 weeks after randomization without compromising safety. (ACTIVE-ADHF [Effects of Acute Phase Intensive Exercise Training in Patients with Acute Decompensated Heart Failure]; <span><span>UMIN000020919</span><svg><path></path></svg></span>)</div></div>","PeriodicalId":14687,"journal":{"name":"JACC. Heart failure","volume":"13 6","pages":"Pages 912-922"},"PeriodicalIF":10.3,"publicationDate":"2025-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143023511","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}